Betterlife Pharma Inc. (TSE:BETR) has released an update.
BetterLife Pharma Inc. is making significant strides in the development of BETR-001, a non-hallucinogenic LSD derivative aimed at treating mental disorders, with the initiation of IND-enabling studies and GLP toxicology assessments. The company has also secured funding through a tranche of Convertible Debentures to support the continued advancement of BETR-001, targeting an IND filing by the end of 2024. Alongside BETR-001, BetterLife is developing BETR-002 for anxiety-related disorders and is exploring strategic options for a drug candidate addressing viral infections.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
